Eli Lilly and Co
Alphabet taps Eli Lilly’s Anat Ashkenazi as new CFO
A check out of Google Headquarters in Mountain Check out, California, United States on April 16, 2024. Tayfun Coskun | Anadolu | Getty Images Eli Lilly CFO Anat Ashkenazi will grow to be Alphabet’s new chief fiscal officer productive July 31, Google’s mother or father organization declared Tuesday, just about a calendar year just after […]
Read More
Why half of all workers may struggle to get weight-loss drug health insurance coverage
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Companies are increasing access to new blockbuster weight-loss drugs for employees, but size of employer may make a big difference in early access. Small businesses and their workers are often stuck […]
Read More
Wells Fargo CEO talks up reasons to love the stock — plus, what’s behind the market drop
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market pressure : The major stock benchmarks were moving lower Wednesday, with the Dow getting the worst of it again. Adding pressure on equities, bond yields […]
Read More
Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages
GLP-1 Supply Tracker from Ro. Courtesy: Ro Telehealth company Ro on Wednesday launched a new tracker to help patients find a popular class of weight loss and diabetes drugs called GLP-1s amid shortages of those treatments in the U.S. The supply tracker could be a valuable tool for many Americans scrambling to get their hands […]
Read More
Buyers have designed these 9 AI plays their main holdings, Financial institution of America facts reveals
Fund managers’ really like for synthetic intelligence-linked stocks has grown as lots of of these tech businesses have turn out to be their vital holdings in the portfolio, according to Lender of America’s investigation. The Wall Avenue firm seemed at the holdings of U.S. big-cap equity mutual funds that are actively managed. It screened the […]
Read More
This new weight loss drug ETF bets big on two of the industry’s leading players
ETF Edge This new weight loss drug ETF bets big on two of the industry’s leading players Published Mon, May 27 202412:01 PM EDT Anna Gleason@anna_gle WATCH LIVE Source
Read More
How digital health companies are capitalizing on the GLP-1 boom
Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end. Michael Siluk | UCG | Getty Images For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had […]
Read More
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Eli Lilly on Friday said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana to boost supply of its highly popular weight loss drug Zepbound, diabetes treatment […]
Read More
This up-and-coming cancer treatment could be a $25 billion market opportunity — it’s already a hotbed for M&A
Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 […]
Read More
A corner of the cancer therapy market is heating up—Here are the names investors need to know
There’s been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis and a slew of clinical […]
Read More